Quintiles expands kidney disease trial offering with DaVita deal

Quintiles ($Q) has teamed up with kidney care specialist DaVita Clinical Research in a deal designed to help shore up offerings in renal disease clinical trials.

DaVita Clinical Research, part of DaVita Healthcare Partners, is a major healthcare player, working with more than one million patients--patients that can be sought for clinical trials.

In a joint statement, both companies point out the studies for patients with kidney problems are becoming more complex in terms of how they are put together, while biopharmas are calling for broader patient populations.

In this collab, financial details of which were not disclosed, the two companies said they will come together in order to: “Provide capabilities and solutions for overcoming these challenges to deliver end-to-end support for renal disease clinical trials.”

They added in a statement: “By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita’s extensive patient understanding, biopharmaceutical customers will be able to take advantage of the combined assets of both companies to progress their clinical programs.”

Amy Young, VP and general manager of DaVita Clinical Research, said: “This alliance allows novel approaches to clinical development and clinical trial execution specifically in site identification, participant enrollment and study design. We are excited about the opportunities this affords our organizations to provide innovative solutions to the biopharmaceutical industry and the participants we serve.”

- check out the release

Related Articles:
Quintiles, IMS Health unveil surprise megamerger
Quintiles bets on a big 2016 as revenue rolls in

Read more on